DANBIO—powerful research database and electronic patient record
ML Hetland - Rheumatology, 2011 - academic.oup.com
The nationwide DANBIO registry has been designed to capture operational clinical data as
part of routine clinical care. At the same time, it provides a powerful research database. This …
part of routine clinical care. At the same time, it provides a powerful research database. This …
The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO
EH Ibfelt, DV Jensen, ML Hetland - Clinical epidemiology, 2016 - Taylor & Francis
Introduction DANBIO is a research register and a data source for rheumatologic diseases
(rheumatoid arthritis [RA], axial spondyloarthritis, and psoriatic arthritis) for monitoring …
(rheumatoid arthritis [RA], axial spondyloarthritis, and psoriatic arthritis) for monitoring …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
JS Smolen, RBM Landewé, JWJ Bijlsma… - Annals of the …, 2020 - ard.bmj.com
Objectives To provide an update of the European League Against Rheumatism (EULAR)
rheumatoid arthritis (RA) management recommendations to account for the most recent …
rheumatoid arthritis (RA) management recommendations to account for the most recent …
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab …
ML Hetland, IJ Christensen, U Tarp… - … : Official Journal of …, 2010 - Wiley Online Library
Objective To compare tumor necrosis factor α inhibitors directly regarding the rates of
treatment response, remission, and the drug survival rate in patients with rheumatoid arthritis …
treatment response, remission, and the drug survival rate in patients with rheumatoid arthritis …
MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial …
ML Hetland, B Ejbjerg, K Hørslev-Petersen… - Annals of the …, 2009 - ard.bmj.com
Objective: To identify predictors of radiographic progression in a 2-year randomised, double-
blind, clinical study (CIMESTRA) of patients with early rheumatoid arthritis (RA). Methods …
blind, clinical study (CIMESTRA) of patients with early rheumatoid arthritis (RA). Methods …
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist …
K Chatzidionysiou, E Lie, E Nasonov… - Annals of the …, 2011 - ard.bmj.com
Objective To assess the 6-month effectiveness of the first rituximab (RTX) course in
rheumatoid arthritis (RA) and to identify possible predictors of response. Method 10 …
rheumatoid arthritis (RA) and to identify possible predictors of response. Method 10 …
Health-related quality of life: validity, reliability, and responsiveness of SF-36, EQ-15D, EQ-5D, RAQoL, and HAQ in patients with rheumatoid arthritis
L Linde, J Sørensen, M Østergaard… - The Journal of …, 2008 - jrheum.org
Objective To compare validity, reliability, and responsiveness of generic and disease
specific health-related quality of life (HRQOL) instruments in rheumatoid arthritis (RA) …
specific health-related quality of life (HRQOL) instruments in rheumatoid arthritis (RA) …
Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti–tumor necrosis factor α therapy: results from the …
B Glintborg, M Østergaard, L Dreyer… - Arthritis & …, 2011 - Wiley Online Library
Objective To investigate disease activity, treatment response, and drug survival, and
predictors thereof, among Danish patients with psoriatic arthritis (PsA) receiving their first …
predictors thereof, among Danish patients with psoriatic arthritis (PsA) receiving their first …
Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' …
B Glintborg, M Østergaard, NS Krogh… - Annals of the …, 2010 - ard.bmj.com
Objectives To use prospectively registered data from the Danish nationwide rheumatological
database (DANBIO) to describe disease activity, clinical response, treatment duration and …
database (DANBIO) to describe disease activity, clinical response, treatment duration and …
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO …
B Glintborg, IJ Sørensen, AG Loft… - Annals of the …, 2017 - ard.bmj.com
Objectives According to guidelines, a nationwide non-medical switch from originator (INX,
Remicade) to biosimilar infliximab (Remsima, CT-P13) was conducted in Danish patients …
Remicade) to biosimilar infliximab (Remsima, CT-P13) was conducted in Danish patients …